

NEWS RELEASE

Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

-- Ablexis Looks Forward to Establishing Additional Non-Exclusive Partnerships in 2017 --

BURLINGAME, Calif. – February 14, 2017 – [Ablexis](#), LLC today announced a licensing agreement for its AlivaMab Mouse technology with Janssen Biotech, Inc. (Janssen). The perpetual, non-exclusive license provides Janssen access to the AlivaMab Mouse platform and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. Ablexis will receive an eight-figure up-front payment.

“Ablexis is pleased to add Janssen to the growing list of companies that have licensed the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This license further affirms the recognition by the world’s leading pharmaceutical companies of the power of the AlivaMab Mouse for rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability. Ablexis remains dedicated to making the AlivaMab Mouse broadly available for antibody drug discovery through flexible partnering strategies.”

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple global pharmaceutical companies and continues making the AlivaMab Mouse available via non-exclusive licenses. The company was founded in 2009 and is based in Burlingame, California; more information can be found by visiting the Company’s website at www.ablexis.com.

###

Ablexis Corporate Contact:
Ablexis, LLC
Larry Green, (415) 967-1220
info@ablexis.com

Ablexis Media Contact:
Red House Communications
Denise Powell, (510) 703-9491
denise@redhousecomms.com